The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On October 31, 2023, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's New Drug Application (NDA) for mavorixafor ...
Treatment with Xolremdi also results in a 60% reduction in the annualized infection rate compared with placebo-treated patients. The company has set a wholesale acquisition cost for Xolremdi annually ...
X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the upcoming European Hematology Association Congress regarding the positive results from their Phase 2 trial of ...
(RTTNews) - X4 Pharmaceuticals (XFOR) announced Monday the presentation of positive results from its completed Phase 2 clinical trial of mavorixafor for the treatment of primary chronic neutropenia or ...
BOSTON, April 29, 2026 (GLOBE NEWSWIRE)-- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, announced today that the European ...
BOSTON and DUBAI, United Arab Emirates, Feb. 19, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, ...
AMSTERDAM, April 29, 2026 /PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company, today announced that the European Commission (EC) has granted marketing authorisation for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results